Long-term follow-up of recovered MPN patients with COVID-19
Posted: Sat Sep 04, 2021 2:00 pm
Afternoon all...
Just in case any of us do suffer from an 'Acute CV-19' experience, this article and subsequent video discusses what might be the likelihood of ongoing complications for those of us with an MPN.
While it does suggest greater fatality rates for MF patients, it also highlights Venous Thrombolelic Events (VTE) for those with Essential Thrombocythaemia (ET) too. It goes on to suggest the possibility of ongoing lingering or (Long Covid symptom burden), which incidentally appear to be primarily something that all if not most of us already know, Fatigue & other related MPN symptoms. Hence, the suggestion that this might happen in up to 40% of the patient cohort, might also be seen as MPN progression, in my view...
Be interested in your thoughts as always...
Best wishes, stay safe & well...
Steve
REFERENCE
Barbui T, De Stefano V, Alvarez-Larran A, et al. 2021."Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19." Blood Cancer J. 2021;11(2):21. DOI: 1038/s41408-021-00417-3
https://mpn-hub.com/medical-information ... g-covid-19
Barbui, T., Iurlo, A., Masciulli, A. et al. 2021. "Long-term follow-up of recovered MPN patients with COVID-19." Blood Cancer J. 11, 115 (2021). https://doi.org/10.1038/s41408-021-00509-0
Just in case any of us do suffer from an 'Acute CV-19' experience, this article and subsequent video discusses what might be the likelihood of ongoing complications for those of us with an MPN.
While it does suggest greater fatality rates for MF patients, it also highlights Venous Thrombolelic Events (VTE) for those with Essential Thrombocythaemia (ET) too. It goes on to suggest the possibility of ongoing lingering or (Long Covid symptom burden), which incidentally appear to be primarily something that all if not most of us already know, Fatigue & other related MPN symptoms. Hence, the suggestion that this might happen in up to 40% of the patient cohort, might also be seen as MPN progression, in my view...
. (Barbui et al,2021)The overall rate of thromboembolic events in patients with MPN and COVID-19 was 8.6% (n = 14). Strikingly, most of these events were VTE, indicating an association of VTE events observed in this study with COVID-19 rather than MPN, where arterial thrombosis is more common. However, patients with ET and COVID-19 experienced significantly more VTEs compared with patients with PV and MF, where the event rate was similar to patients with COVID-19 but without MPN, who were treated on regular wards. Vascular events occurred shortly after hospitalization and were associated with shorter survival. Independent risk factors for thrombosis were an ET phenotype, elevated NLR, and transfer to ICU. While most thrombotic events occurred within 15 days of COVID-19 onset, bleeding events were more frequent ~2 weeks after COVID-19 onset.
Be interested in your thoughts as always...
Best wishes, stay safe & well...
Steve
REFERENCE
Barbui T, De Stefano V, Alvarez-Larran A, et al. 2021."Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19." Blood Cancer J. 2021;11(2):21. DOI: 1038/s41408-021-00417-3
https://mpn-hub.com/medical-information ... g-covid-19
Barbui, T., Iurlo, A., Masciulli, A. et al. 2021. "Long-term follow-up of recovered MPN patients with COVID-19." Blood Cancer J. 11, 115 (2021). https://doi.org/10.1038/s41408-021-00509-0